leisure time -WSS

leisure time

author：explore 2025-09-30 20:47:41 - browse：5978

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： HPV cancer vaccine study demonstrates efficacy

focus

WSS

Just how powerful is the placebo effect?

Just how powerful is the placebo effect?

Excited delirium, Elijah McClain, and emergency physicians

10 million people disenrolled from Medicaid over past six months

Victims of gun violence feel impacts long after bullet wound

Doctors find melanoma drugs effective against rare brain cancer

focus

leisure time

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How Medicaid coverage policies for immigrants impact new moms

Drug repurposing or repositioning? The language matters

The Sacklers, horror, and ‘The Fall of the House of Usher’

Supreme Court strikes down use of affirmative action

Sanofi CEO defends move to abandon profit guidance, boost research

DIEP, the 'gold standard' of breast reconstruction, is under threat

Sanofi seeks simpler, safer CRISPR sickle cell cure

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The new shift in health care is toward less care

leisure time

Ambulance rides for just $100? Advisers want major billing fixes

Extreme heat events are a public health emergency

FDA approves RSV monoclonal antibody for infants, toddlers

Cosmetics set for new safety regulation. Why the industry is on board

Abortion clinic in Cancun will cater to Americans

Senate panel clears PBM, hopsital reforms

focus

leisure time

knowledge

hotspot